Compare Arm Holdings plc (ARM) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arm Holdings plc vs Charles River Laboratories Intl. Inc — how do they compare? Arm Holdings plc trades at $313.6 (market cap $345.41B), while Charles River Laboratories Intl. Inc trades at $233.41 (market cap $11.24B). The key difference: Arm Holdings plc is far larger — about 30.7× Charles River Laboratories Intl. Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Arm Holdings plc nearer its low. Which is the better fit depends on your goals.
| ARM | CRL | |
|---|---|---|
Market Cap | $345.41B | $11.24B |
Sector | Technology | Health |
52-Week High | $439.46 | $233.60 |
52-Week Low | $104.55 | $145.57 |
Enterprise Value | $342.26B | $14.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARM Holdings trades at $323.39, down 1.37% over 24 hours, with a bullish technical outlook supported by moving averages and strong quarterly earnings beats. The company reported robust revenue growth to $4.01B in 2025, with net income of $792M, though valuation ratios like P/E of 380.46 reflect premium pricing. Recent news highlights ARM's role in AI infrastructure and data center expansion, driving investor optimism.
Outlook remains positive with analyst consensus favoring buy ratings (74.07%) and a $321.65 price target, but risks include high valuation sensitivity and competitive pressures in the semiconductor space. Upside potential hinges on continued AI-driven demand and execution of growth initiatives like the AGI CPU launch.
Charles River Laboratories (CRL) trades at $233.41, down slightly by 0.08% today, with a bullish technical signal supported by moving averages. The company shows strong operational cash flow of $737.65M for 2025 but faces profitability challenges with negative net income margin of -4.59% and ROE of -6.02%. Recent earnings have consistently beaten expectations, and analyst consensus remains strongly positive with 72% buy ratings.
CRL presents a mixed investment case: strong cash generation and strategic collaborations like the Lilly TuneLab partnership provide growth catalysts, but negative profitability metrics and high valuation ratios (P/E 684.85) pose risks. The stock's outlook depends on margin improvement and successful execution of recent business initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arm Holdings plc
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
